| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0dfd28b225eea9234cde9e0ffcd28e40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51819a06e0b14071fd1e57e6ff4acfa5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b9ca445465ed3557192f55652045cc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b811a32478e5784d083649d393c8e01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 |
| filingDate |
2007-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd964ed29beb28b14ba804b486ba0fac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca3f6ea84fff35d342299d85868cbdb7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b9c50256272fba20d2e5ffa3233ad13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a5fc4776c88d54cf0a6407aa46cfc3 |
| publicationDate |
2008-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008048084-B1 |
| titleOfInvention |
Pharmaceutical combinations for the treatment of dyslipidemia accompanied by high blood pressure |
| abstract |
The invention relates to the pharmaceutical industry in general and to the pharmaceutical industry involved in the production of drugs for controlling dyslipidemias accompanied by high arterial blood pressure with an elevated risk of cerebrovascular and cardiovascular thromboembolic ischemic events. More specifically, the invention relates to a composition formed by a HMG-CoA reductase-inhibiting substance known as rosuvastatin calcium, combined with a calcium channel-inhibiting antihypertensive known as amlodipine besylate and a platelet antiaggregate known as acetylsalicylic acid, which produce a product having a synergic effect with smaller delivery doses and lower risks of adverse events. |
| priorityDate |
2006-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |